Total Payments
$113,660
2024 Payments
$9,240
Companies
124
Transactions
2,998
Medicare Patients
8,394
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$62,652 (55.1%)
Consulting$42,690 (37.6%)
Other$4,849 (4.3%)
Education$2,230 (2.0%)
Travel$1,040 (0.9%)
Gifts$200.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $62,652 | 2,909 | 55.1% |
| Consulting Fee | $42,690 | 17 | 37.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,800 | 3 | 3.3% |
| Education | $2,230 | 53 | 2.0% |
| Travel and Lodging | $1,040 | 7 | 0.9% |
| Honoraria | $550.00 | 3 | 0.5% |
| Long term medical supply or device loan | $498.50 | 5 | 0.4% |
| Gift | $200.00 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $27,396 | 179 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13,240 | 115 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $7,156 | 206 | $0 (2024) |
| Exelixis Inc. | $5,412 | 47 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,251 | 217 | $0 (2024) |
| GlaxoSmithKline, LLC. | $3,488 | 144 | $0 (2024) |
| Eisai Inc. | $3,167 | 77 | $0 (2024) |
| PFIZER INC. | $3,079 | 171 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,935 | 149 | $0 (2024) |
| Amgen Inc. | $2,600 | 89 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,240 | 359 | AstraZeneca Pharmaceuticals LP ($652.64) |
| 2023 | $11,749 | 374 | TAIHO ONCOLOGY, INC. ($2,200) |
| 2022 | $17,137 | 356 | Boehringer Ingelheim Pharmaceuticals, Inc. ($4,118) |
| 2021 | $8,728 | 371 | Amgen Inc. ($657.14) |
| 2020 | $19,513 | 318 | AstraZeneca Pharmaceuticals LP ($11,412) |
| 2019 | $26,434 | 421 | AstraZeneca Pharmaceuticals LP ($11,480) |
| 2018 | $10,923 | 401 | Boehringer Ingelheim Pharmaceuticals, Inc. ($3,838) |
| 2017 | $9,937 | 398 | Novartis Pharmaceuticals Corporation ($3,404) |
All Payment Transactions
2,998 individual payment records from CMS Open Payments — Page 1 of 120
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Kowa Pharmaceuticals America, Inc. | ZORYVE (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: DERMATOLOGY | ||||||
| 12/18/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $21.76 | General |
| 12/18/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Genetically Defined Disease | ||||||
| 12/11/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $32.81 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/11/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Oncology | ||||||
| 12/09/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: VACCINES | ||||||
| 12/09/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Diabetes | ||||||
| 12/04/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/02/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug), TGCT | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: VACCINES | ||||||
| 11/25/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: RESPIRATORY | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Oncology | ||||||
| 11/21/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,749 | 3,995 | $359,037 | $188,595 |
| 2022 | 26 | 1,710 | 4,088 | $443,979 | $243,359 |
| 2021 | 28 | 2,623 | 6,063 | $584,291 | $338,667 |
| 2020 | 28 | 2,312 | 6,416 | $552,867 | $272,872 |
Total Patients
8,394
Total Services
20,562
Medicare Billing
$1.0M
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 238 | 829 | $171,354 | $88,028 | 51.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 142 | 503 | $45,959 | $26,514 | 57.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 131 | 226 | $33,039 | $15,888 | 48.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 54 | 54 | $11,340 | $7,974 | 70.3% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 100 | 110 | $14,726 | $7,641 | 51.9% |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | Office | 2023 | 79 | 539 | $8,085 | $6,339 | 78.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 61 | 61 | $6,100 | $4,624 | 75.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 72 | 94 | $6,521 | $3,821 | 58.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $7,638 | $3,819 | 50.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 39 | 48 | $7,076 | $3,146 | 44.5% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 43 | 60 | $5,397 | $2,846 | 52.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 164 | 328 | $5,413 | $2,755 | 50.9% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 105 | 105 | $3,127 | $2,236 | 71.5% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 11 | 12 | $3,916 | $2,145 | 54.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 57 | 57 | $2,850 | $2,000 | 70.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 73 | 75 | $4,316 | $1,867 | 43.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 26 | $3,380 | $1,588 | 47.0% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 139 | 334 | $5,840 | $1,512 | 25.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 31 | 34 | $3,058 | $1,170 | 38.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 68 | 73 | $2,555 | $956.92 | 37.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 58 | $2,360 | $736.68 | 31.2% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 17 | 17 | $724.71 | $503.13 | 69.4% |
| 90471 | Administration of vaccine | Office | 2023 | 13 | 13 | $650.00 | $242.05 | 37.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 19 | 27 | $2,750 | $205.47 | 7.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 11 | 253 | $842.00 | $24.87 | 3.0% |
About Dr. Kin Lam, MD
Dr. Kin Lam, MD is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962442699.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kin Lam, MD has received a total of $113,660 in payments from pharmaceutical and medical device companies, with $9,240 received in 2024. These payments were reported across 2,998 transactions from 124 companies. The most common payment nature is "Food and Beverage" ($62,652).
As a Medicare-enrolled provider, Lam has provided services to 8,394 Medicare beneficiaries, totaling 20,562 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location New York, NY
- Active Since 06/08/2006
- Last Updated 09/25/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1962442699
Products in Payments
- TAGRISSO (Drug) $20,097
- GILOTRIF (Drug) $8,893
- Cabometyx (Drug) $4,815
- Lenvima (Drug) $3,062
- OPDIVO (Biological) $2,947
- PDR001 (Drug) $2,709
- KEYTRUDA (Biological) $2,518
- LONSURF (Drug) $2,290
- IMFINZI (Biological) $1,952
- Yescarta (Drug) $1,758
- ZEJULA (Drug) $1,304
- NINLARO (Drug) $1,142
- KISQALI (Drug) $980.35
- Stivarga (Drug) $960.63
- DARZALEX (Biological) $867.29
- Vascepa (Drug) $826.50
- Enhertu (Drug) $825.08
- TRELEGY ELLIPTA (Drug) $779.58
- Ozempic (Drug) $779.50
- IBRANCE (Drug) $708.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205